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Objective: To characterize the inﬂammatory proﬁles of patients with systemic lupus erythe-
matosus receiving standard treatment compared to healthy controls.
Patients and methods: Peripheral venous blood was collected from systemic lupus erythe-
matosus patients (n = 14) and controls (n = 18) at enrollment. Blood samples were used
for  quantiﬁcation, by ﬂow cytometry, of CD11b (integrin) and Chemokine receptor CXCR2
expression surface antigen in neutrophils and lymphocytes, while cytokines were assayed
in  serum samples. Puriﬁed neutrophils were assayed by their ability to phagocytize human
plasma-opsonized zymosan.
Results: Patients had a median (interquartile range) disease activity index of 1.0 (0–2.0) char-
acteristic of patients in remission. Interleukin-6 and interleukin-10 serum concentrations
were signiﬁcantly higher in the patient group compared to controls and the phagocytic index
of  circulating neutrophils was signiﬁcantly reduced in patients compared to controls. The
levels of interleukin-2, interleukin-5, interleukin-8 and tumor necrosis factor alpha did not
signiﬁcantly differ between patients and controls. Flow cytometric analysis revealed that the
integrin expression levels were reduced in lymphocytes (but not in neutrophils) obtained
from systemic lupus erythematosus patients, while surface expression of the chemokine
receptor 2 was similar in both neutrophils and lymphocytes.
Conclusion: Systemic lupus erythematosus patients receiving standard treatment presented
with  elevated systemic levels of interleukin-6 and interleukin-10, reduced neutrophil phago-
cytic  capacity, and reduced lymphocyte expression of integrin even when symptoms were
in  remission. These alterations to innate immune components may put these individualsat  a greater risk for acquiring infections.
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Caracterizac¸ão de  marcadores  inﬂamatórios  associados  a  pacientes
com  lúpus  eritematoso  sistêmico  em  tratamento
Palavras-chave:
Lúpus eritematoso sistêmico
Citocinas
Fagocitose
Integrina
CXCR2
r  e  s  u  m  o
Objetivo: Caracterizar os perﬁs inﬂamatórios de pacientes com lúpus eritematoso sistêmico
que  estavam recebendo tratamento padrão em comparac¸ão com controles saudáveis.
Pacientes e métodos: Coletou-se o sangue venoso periférico de pacientes com LES (n = 14) e con-
troles  (n = 18) no momento da entrada no estudo. As amostras de sangue foram usadas para
quantiﬁcac¸ão, por citometria de ﬂuxo, da expressão dos antígenos de superfície CD11b (inte-
grina) e do receptor de quimiocina CXCR2 em neutróﬁlos e linfócitos, enquanto as citocinas
foram avaliadas em amostras de soro. Avaliou-se a capacidade dos neutróﬁlos puriﬁcados
de  fagocitar zimosan opsonizado com plasma humano.
Resultados: Os pacientes apresentavam uma pontuac¸ão mediana (intervalo interquartil) no
índice de atividade da doenc¸a de 1,0 (0–2,0), característica de pacientes em remissão. As
concentrac¸ões séricas de interleucina 6 e interleucina 10 foram signiﬁcativamente maiores
no grupo de pacientes em comparac¸ão com os controles; o índice de fagocitose de neu-
tróﬁlos circulantes estava signiﬁcativamente reduzido nos pacientes em comparac¸ão com
os  controles. Os níveis de interleucina 2, interleucina 5, interleucina 8 e fator de necrose
tumoral alfa não diferiram signiﬁcativamente entre pacientes e controles. A análise da cit-
ometria de ﬂuxo revelou que os níveis de expressão da integrina estavam reduzidos nos
linfócitos (mas não nos neutróﬁlos) obtidos de pacientes com lúpus eritematoso sistêmico,
enquanto a expressão do receptor de superfície de quimiocina era semelhante em neutró-
ﬁlos  e linfócitos.
Conclusão: Os pacientes com lúpus eritematoso sistêmico recebendo tratamento padrão
apresentaram níveis sistêmicos elevados de interleucina 6 e interleucina 10, reduc¸ão na
capacidade fagocítica dos neutróﬁlos e expressão reduzida da integrina em linfócitos,
mesmo quando os sintomas estavam em remissão. Essas alterac¸ões nos componentes da
imunidade inata podem colocar esses indivíduos em maior risco de adquirir infecc¸ões.
©  2016 Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma licenc¸a CCIntroduction
Systemic lupus erythematosus (SLE) is an autoimmune
disease involving both T-cell and B-cell abnormalities char-
acterized by the loss of tolerance to nuclear self antigens
and the production of autoantibodies that cause inﬂamma-
tion and damage to multiple organ systems.1 An increasing
array of cytokine abnormalities has been implicated in either
the pathogenesis of SLE or as secondary markers that reﬂect
immune dysregulation.2,3
One of the characteristics of chronic inﬂammation is dys-
regulation of the chemokine network, including changes to the
expression proﬁles of CXCR2 and CXCR3. CXCR2 is a G-protein
coupled receptor belonging to the CXC chemokine family that
serves as a receptor for IL-8 (CXCL8) and CXCL1 that mediates
neutrophil recruitment, cell proliferation, and angiogenesis.4,5
The CD11b/CD18 integrin (Mac-1, complement receptor 3)
is a surface receptor expressed by monocytes, macrophages,
neutrophils, dendritic cells, and B cell subsets that binds
several ligands including members of the ICAM family and
the complement factor iC3b. It is involved in essential
immunological processes including leukocyte extravasation
and phagocytosis. A single nucleotide polymorphism in the
integrin extracellular domain resulting in an amino acid
change represents one of the strongest genetic risk factors
associated with human SLE.6,7BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The variant form is associated with reduced cell adhesion
to ICAM-1, ICAM-2, and iC3b and with impaired phagocy-
tosis, suggesting that this polymorphism (that affects the
efﬁcient removal of apoptotic cells) is associated with dis-
ease pathology. Changes to phagocytosis efﬁcacy are not
restricted to CD11b+/CD18+ macrophages but also to other
phagocytic cells such as monocytes and neutrophils.7 Fur-
thermore, this polymorphism is associated with impaired
regulation of inﬂammatory cytokine networks possibly asso-
ciated with SLE disease progression.6,8
The impaired leukocyte function (i.e., monocytes and neu-
trophils) observed in SLE patients places these individuals
at increased risk for acquiring bacterial infections associ-
ated with increased rates of morbidity and mortality.9 In
addition to decreased phagocytosis of microbial pathogens,
impaired clearance of apoptotic cells negatively impacts tissue
homeostasis by exposing the immune system to intracellu-
lar components that are pro-inﬂammatory and immunogenic,
thereby contributing to the development of chronic inﬂamma-
tion and autoimmune disorders.10
Treatment with prednisolone failed to modify the CD11b
expression on peripheral blood neutrophils in patients
with ulcerative colitis compared with controls.11 However
dexamethasone inhibited membrane, but not intracellular,
expression of CD11b on murine eosinophils, associated to
reduced cell chemotaxis.12 Considering the CD11b polymor-
phism in LES patients and possible impairment of corticoids
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n functional leukocyte capacity, patients with LES under
reatment may be susceptible to functional deﬁcit in circu-
ating immune cells.
The present study was designed to further character-
ze the inﬂammatory response presenting in SLE patients
ndergoing treatment by comparing the systemic cytokine
esponse, neutrophil phagocytic capacity, and the CD11b and
XCR2 neutrophil and lymphocyte expression proﬁles in both
atients and controls.
aterials  and  methods
atients
omen referred by the public health system to the Out-
atient Rheumatology Service of the Federal University of
riângulo Mineiro (UFTM) were prospectively diagnosed with
LE according to guidelines established by the American Col-
ege of Rheumatology and enrolled in the study. Patients had
ifferent times of SLE onset and were being treated with
orticoids and/or hydroxychloroquine and/or azathioprine.
isease severity was established using the Systemic Lupus
rythematosus Disease Activity Index (SLEDAI) score system.
ealthy female volunteers served as controls. The study pro-
ocol was approved by the UFTM Committee on the Use of
uman Subjects, and written informed consent was obtained
rom all patients and controls.
lood  collection
eripheral venous blood samples were collected from patients
nd controls at enrollment. At each collection time two sam-
les (5 mL  each) were collected (with or without 100 IU/mL
eparin). Sera were obtained by centrifuging (180 × g) the blood
or 15 min. Respective serum samples were then collected and
tored at −70 ◦C until use. The assays were performed at the
aboratory of the Discipline of Pharmacology and at the Onco-
ogical Research Institute (IPON)/Discipline of Gynecology and
bstetrics.
uantiﬁcation  of  serum  cytokine  levels
he serum levels of TNF-, IL-2, IL-5, IL-6, IL-8, and IL-
0 were determined by ELISA. Brieﬂy, ﬂat-bottomed 96-well
icrotiter plates were coated with antibodies (1–3 g/mL in
0 L/well) speciﬁc for each cytokine in binding buffer and
ncubated overnight (4 ◦C). Plates were then washed with
hosphate buffered saline-Tween-20 (PBST) and nonspeciﬁc
inding blocked by incubating wells with 100 L/well PBS/1%
ovine serum albumin (BSA) for 120 min  at 37 ◦C. Samples
nd standards were added to respective wells (50 L/well)
nd incubated overnight (4 ◦C). Plates were washed with PBST
ollowed by the addition of the appropriate biotinylated mono-
lonal anti-cytokine antibody. After 1 h, plates were washed
nd avidin peroxidase (diluted 1:5000) added to each well.
fter 30 min  the plates were washed and substrate (100 L
-phenylenediamine dihydrochloride [OPD, Sigma, St. Louis,
O]) was added. The plates were subsequently incubated at
oom temperature for 15 min  before H2SO4 (50 L, 1 M)  was 6;5 6(6):497–503 499
added to each well to stop the reaction and the optical density
measured at 490 nm using a multiwell plate reader (Multi-
skan MCC340 MKII, Flow Laboratories). Data are expressed in
picograms of cytokine/mL serum. Cytokine concentrations in
serum samples were determined from the standard curves
generated.
CD11b  and  CXCR2  expression  by  neutrophils
and lymphocytes
CD11b and CXCR2 expression levels were quantiﬁed using a
FACSCalibur ﬂow cytometer and CellQuestTM software (Bec-
ton Dickinson, San Jose, CA), with acquisition of 10.000
cells in each experiment. Phycoerythrin (PE)-conjugated anti-
CD11b antibody, PE/Cy5-conjugated anti-CXCR2 antibody (BD
Pharmingen, San Diego, CA), and control antibodies (PE- or
PECy-5-conjugated IgG2b; BD Pharmingen, San Diego, CA) were
used. Data are expressed as the number of absolute or the per-
centage of neutrophils and lymphocytes positive for CD11b
and/or CXCR2 expression.
Phagocytosis  assay
The phagocytosis index of neutrophils (2 × 106/mL) harvested
from either SLE patients or healthy controls was assessed
by their ability to phagocytize human plasma-opsonized
zymosan (10 particles/cell) over a 1 h period at 37 ◦C (5% CO2).
The phagocytic index is expressed as follows: % of phagocytic
cells × number of interiorized particles.
Statistical  analysis
Statistical analyses were performed using SigmaStat 2.03
software. Distribution was evaluated using the Kolmogorov–
Smirnov test and differences between two unpaired groups
(SLE patients vs. controls) were determined using the Stu-
dent’s t test or the Mann–Whitney test according to normal
or not normal distribution of the data, respectively. Statistical
signiﬁcance was set at p ≤ 0.05.
Results
Study  population
Fourteen women diagnosed with SLE (mean time with dis-
ease ± SD of 7.1 ± 4.3 y), mean age (±SD) of 40.6 ± 9.6 y (range,
24–55) and 18 healthy women, mean age of 35.3 ± 9.8 y (range,
26–55) were enrolled into the study (Table 1). Age did not dif-
fer between patients and controls (p = 0.132, Student’s t test).
The median (and interquartile) SLEDAI score was 1.0 (0–2.0),
indicating that SLE was in clinical remission. In eight patients
(57.2%) the SLEDAI score was zero, three patients (21.4%) had a
score of 2, two (14.3%) patients had a score of 4 (moderate dis-
ease activity), and one patient (7.1%) had score of 9 (moderate
activity) (Table 1).The treatment received by SLE patients at enrollment is
described in Table 1. Three (21.4%) patients were treated with
only corticoids (prednisone or prednisolone), 2/14 (14.3%)
received hydroxychloroquine, 6/14 (42.9%) received both
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Table 1 – Systemic lupus erythematosus (SLE) patient
characteristics and disease parameters.
Number of patients 14
Average age ± SD, years 40.6 ± 9.6
Age range 24–55
Sex (female/male), n 14/0
Disease duration (mean ± SD), years 7.1 ± 4.3
Disease duration range, years 1–15
SLEDAI score, medians (25–75%) 1.0 (0–2.0)
SLEDAI score, n (%)
Zero 8 (57.2%)
2 3 (21.4%)
4 2 (14.3%)
9 1 (7.1%)
Treatment, n (%)
Corticoids 3 (21.4%)
Hydroxychloroquine 2 (14.3%)
Corticoids plus hydroxychloroquine 6 (42.9%)
Corticoids or hydroxychloroquine plus azathioprine 3 (21.4%)
Table 2 – SLE and control serum cytokine concentrations
(pg/mL).
Cytokines (pg/mL) Controls (n = 18) Patients (n = 14)
IL-2 9.6 (5.3–19.1) 7.3 (6.5–12.8)
IL-5 11.6 (4.5–25.1) 4.4 (2.8–7.7)
IL-6 3.9 (2.6–5.2) 6.8 (5.2–8.5)a
IL-8 13.2 (11.5–23.6) 21.3 (17.2–31.3)b
IL-10 0.0 (0.0–4.5) 13.5 (0–17.2)c
TNF- 0.0 (0.0–3.5) 1.3 (0.2–3.1)
Data are expressed as medians (interquartile range).
a p < 0.01.
controls, leading to IL-8 hypo-responsiveness in vitro.5 Theb p = 0.115 compared to the control group (Mann–Whitney test).
c p < 0.05.
corticoids and hydroxychloroquine, and 3/14 (21.4%) received
azathioprine plus corticoid or hydroxychloroquine.
Serum  cytokine  concentrations
Serum cytokine levels were characterized in both patients and
controls. The median serum levels of TNF-, IL-2, and IL-5 did
not differ signiﬁcantly between groups (Table 2). IL-8 levels
were elevated in SLE patients compared to controls but the lev-
els were not statistically signiﬁcant (p = 0.115). But the serum
concentrations of IL-6 (p < 0.01) and IL-10 (p < 0.05) were sig-
niﬁcantly higher in SLE patients at enrollment compared to
controls (Table 2).
CD11b  and  CXCR2  expression  by  neutrophils
and lymphocytes
The surface expression of CD11b and CXCR2 by neutrophils
and lymphocytes harvested from patients (n = 14) and a sub-
set of randomly selected controls (n = 16) was assessed by ﬂow
cytometry. The absolute number of lymphocytes harvested
from SLE patients expressing CD11b was lower compared to
expression levels observed in controls (Fig. 1C). No differences
in CD11b expression by neutrophils were detected (Fig. 1A
and B). The number of CXCR2 positive cells did not differ in 0 1 6;5 6(6):497–503
either neutrophils (Fig. 2A and B) or lymphocytes (Fig. 2C and
D) harvested from patients and controls.
Phagocytosis  assay
The ability of neutrophils harvested from patients (n = 14)
and controls (n = 18) to phagocytize opsonized zymosan was
evaluated. Neutrophils from SLE patients presented with a
signiﬁcantly lower median (interquartile range) phagocytic
activity index, 178.0 (49.0–304.0) compared to control neu-
trophils, 577.0 (209.0–1131.0) (p = 0.017, Mann–Whitney).
Discussion
The present study deﬁned the inﬂammatory cytokine proﬁle
of SLE patients undergoing therapy. As expected, all patients
enrolled were women since SLE is nine times more  common in
women than in men.1 Increased serum levels of IL-6 and IL-10
were detected in SLE patients compared to controls although
the levels of TNF-, IL-2, IL-5 and IL-8 did not differ between
groups.
The nucleosome is a major autoantigen that can be
detected as a complex in the serum of SLE patients with
the potential of directly activating neutrophils.13 This was
conﬁrmed by incubating neutrophils from healthy individ-
uals with plasma obtained from SLE patients that responded
by producing increased levels of pro-inﬂammatory cytokines
such as TNF-, IL-6, and IL-8.14
IL-6 is likely to be involved in autoantibody production in
SLE patients.3 Data presented in this report demonstrated sig-
niﬁcantly elevated IL-6 serum levels in SLE patients compared
to controls, according to other studies.15,16 It was reported that
the levels of IL-6 correlated with the IL-12 and IL-23 levels
observed at the time of SLE diagnosis and after prednisone
treatment was initiated.15
Serum IL-8 levels were elevated in lupus patients but
not signiﬁcantly. SLE patients with active or inactive disease
presented with elevated levels of chemoattractant proteins,
including IL-8, compared to controls, regardless of the drug
treatment regimen used and the degree of tissue damage.17
The authors suggest that long-term treatment of SLE with
standard immunomodulatory drug regimens fails to normal-
ize the levels of key chemoattractant proteins linked to innate
immunity and that a baseline pro-inﬂammatory state persists
in SLE patients.17
High systemic concentrations of chemokines such as IL-
8 have the potential of inducing receptor desensitization and
rendering leukocytes unresponsive to subsequent exposure.18
Our present data did not identify differences in the CXCR2
expression levels on circulating neutrophils or lymphocytes,
maybe, in part, because serum IL-8 levels did not reach higher
signiﬁcant levels in patients compared to controls. But other
studies have demonstrated that neutrophils from SLE patients
had decreased CXCR2 gene expression levels, compared toCXCR2 expression levels in T cells were increased in patients
with active SLE compared to patients with inactive disease and
to healthy controls.4
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Fig. 1 – Analysis of CD11b expression. Neutrophils obtained from either controls (n = 16) or Systemic lupus erythematosus
(SLE) patients (n = 14) under treatment were  analyzed by ﬂow cytometry. The absolute numbers (panels A and C) and
percentages (panels B and D) of neutrophils (panels A and B) and lymphocytes (panels C and D) positive for CD11b are
shown. The 25th and 75th percentiles are represented by a bar centered around the median. The minimum and maximum
values are represented by error bars. *p < 0.05 compared to the respective control (Student’s t test).
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Fig. 2 – Analysis of CXCR2 expression. Neutrophils obtained from either controls (n = 16) or SLE patients (n = 14) under
treatment were  analyzed by ﬂow cytometry. The absolute numbers (panels A and C) and percentages (panels B and D) of
neutrophils (panels A and B) and lymphocytes (panels C and D) positive for CXCR2 are shown. The 25th and 75th percentiles
are represented by a bar centered around the median and the minimum and maximum values are represented by error bars.
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The role of IL-10 in SLE is somewhat controversial. IL-10 is
generally considered an anti-inﬂammatory and an immuno-
suppressive cytokine. However, it is overexpressed in lupus
patients and in some cases has been reported to act as a lupus-
promoting molecule.2 Several studies have demonstrated that
the serum/plasma IL-10 levels were markedly increased in
SLE patients compared to controls,19 as shown in the present
study.
Increased IL-10 levels have been correlated with disease
activity or with the production of autoantibodies that can
contribute to SLE pathogenesis19 and/or modulate the differ-
entiation and function of dendritic cells. Monocyte-derived
dendritic cells activated by either SLE serum or following
exposure to exogenous IL-10 had reduced expression levels
of human leukocyte antigen (HLA)-DR and exhibited impaired
capacity to stimulate allogenic T-cell proliferation.20
Cells expressing a CD11b polymorphism displayed
increased IL-6 production compared to wild type-CD11b-
expressing cells and this genetic polymorphism resulted in
an integrin isoform incapable of mediating cell adhesion
via interactions with either ICAMs or iC3b.6 Data presented
in this report showed that the CD11b expression proﬁle on
neutrophils was similar between SLE patients and controls;
however, a reduced absolute number of lymphocytes from
SLE patients expressed CD11b. This deﬁciency may ultimately
lead to immune system malfunction and contribute to the
development of SLE.6
The present study also detected that the neutrophil phago-
cytic index was reduced in SLE patients compared with
controls, a ﬁnding that, associated to reduced expression of
CD11b, may put these individuals at a greater risk for devel-
oping infections. Continuous exposure to nucleosomes may
partly explain the observed reduction in activity associated
with polymorphonuclear neutrophis (PMN) isolated from SLE
patients, as well as the reduced PMN  counts and the general
state of inﬂammation observed in these individuals.14 It has
been reported that lupus patients presented with low-density
circulating neutrophils have an altered phagocytic potential
despite their proinﬂammatory phenotype (deﬁned by their
cytokine proﬁle).21
A study comparing the function of neutrophils among
pediatric-onset SLE patients and healthy subjects demon-
strated that regardless of infection status, medication, and
disease severity, SLE patients had an impaired ability to
phagocytize Salmonella-speciﬁc lipopolysaccharides compared
to controls.9 In addition, macrophages isolated from patients
with untreated SLE phagocytized apoptotic neutrophils less
effectively than neutrophils harvested from healthy donors,10
thereby contributing to the development of chronic inﬂamma-
tion and autoimmunity.
Of note, our results demonstrate, at a same time point,
associated alterations in parameters of the innate immune
response, even when SLE patients were mainly with inactive
disease, pointing to a potential mechanism for susceptibil-
ity to infections. But a limitation of the present study is
the small number of patients. Also, although most patients
had disease in remission, the study design did not evaluate
the individual role of disease activity in the inﬂammatory
proﬁle of patients. Additional research with a larger patient
population and with patient groups at the same grade of
1 0 1 6;5 6(6):497–503
disease activity would favor a more  accurate comparison of
results.
In conclusion, SLE patients receiving immunosuppressive
treatment presented with elevated systemic levels of IL-6 and
IL-10, reduced neutrophil phagocytic capacity, and reduced
lymphocyte expression of CD11b. These associated ﬁndings
were present even when symptoms were mainly in remission,
suggesting that these alterations to innate immune compo-
nents may put these individuals at a greater risk for developing
infections.
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